To do so, we utilized an isogenic pancreatic ductal adenocarcinoma cell line (PATU-8902 FKBP12F36V-KRASG12V; KRAS–/–) that we previously developed to study KRASG12V degradation in vitro (29). This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.